栄研化学の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2026/02/19 | 2,540 | 2,557 | 2,517 | 2,546 | +4 | +0.2% | 68,800 |
| 2026/02/18 | 2,559 | 2,566 | 2,531 | 2,542 | +8 | +0.3% | 45,400 |
| 2026/02/17 | 2,551 | 2,564 | 2,530 | 2,534 | +2 | +0.1% | 57,200 |
| 2026/02/16 | 2,558 | 2,560 | 2,515 | 2,532 | -28 | -1.1% | 71,400 |
| 2026/02/13 | 2,572 | 2,585 | 2,545 | 2,560 | -8 | -0.3% | 71,200 |
| 2026/02/12 | 2,546 | 2,580 | 2,544 | 2,568 | +50 | +2% | 102,000 |
| 2026/02/10 | 2,504 | 2,542 | 2,502 | 2,518 | +32 | +1.3% | 67,400 |
| 2026/02/09 | 2,514 | 2,514 | 2,464 | 2,486 | +22 | +0.9% | 57,100 |
| 2026/02/06 | 2,498 | 2,498 | 2,454 | 2,464 | -51 | -2% | 63,200 |
| 2026/02/05 | 2,552 | 2,556 | 2,503 | 2,515 | -37 | -1.4% | 135,900 |
| 2026/02/04 | 2,474 | 2,571 | 2,474 | 2,552 | +78 | +3.2% | 152,800 |
| 2026/02/03 | 2,527 | 2,537 | 2,474 | 2,474 | -57 | -2.3% | 100,700 |
| 2026/02/02 | 2,549 | 2,585 | 2,499 | 2,531 | +139 | +5.8% | 269,800 |
| 2026/01/30 | 2,400 | 2,421 | 2,375 | 2,392 | -8 | -0.3% | 77,700 |
| 2026/01/29 | 2,417 | 2,442 | 2,372 | 2,400 | -17 | -0.7% | 78,600 |
| 2026/01/28 | 2,467 | 2,476 | 2,417 | 2,417 | -67 | -2.7% | 73,700 |
| 2026/01/27 | 2,455 | 2,496 | 2,452 | 2,484 | +10 | +0.4% | 58,800 |
| 2026/01/26 | 2,467 | 2,505 | 2,460 | 2,474 | -38 | -1.5% | 63,200 |
| 2026/01/23 | 2,496 | 2,516 | 2,479 | 2,512 | +37 | +1.5% | 46,100 |
| 2026/01/22 | 2,425 | 2,492 | 2,425 | 2,475 | +50 | +2.1% | 64,000 |
| 2026/01/21 | 2,431 | 2,443 | 2,415 | 2,425 | -26 | -1.1% | 62,900 |
| 2026/01/20 | 2,435 | 2,470 | 2,435 | 2,451 | -5 | -0.2% | 59,400 |
| 2026/01/19 | 2,459 | 2,483 | 2,452 | 2,456 | +4 | +0.2% | 46,300 |
| 2026/01/16 | 2,432 | 2,455 | 2,432 | 2,452 | +14 | +0.6% | 42,100 |
| 2026/01/15 | 2,426 | 2,454 | 2,426 | 2,438 | -12 | -0.5% | 52,200 |
| 2026/01/14 | 2,460 | 2,481 | 2,443 | 2,450 | -15 | -0.6% | 60,000 |
| 2026/01/13 | 2,473 | 2,483 | 2,439 | 2,465 | +2 | +0.1% | 67,800 |
| 2026/01/09 | 2,534 | 2,538 | 2,453 | 2,463 | -61 | -2.4% | 128,400 |
| 2026/01/08 | 2,467 | 2,541 | 2,467 | 2,524 | +66 | +2.7% | 120,600 |
| 2026/01/07 | 2,440 | 2,537 | 2,440 | 2,458 | +44 | +1.8% | 145,600 |
| 2026/01/06 | 2,396 | 2,424 | 2,396 | 2,414 | +11 | +0.5% | 47,300 |
| 2026/01/05 | 2,391 | 2,415 | 2,380 | 2,403 | -4 | -0.2% | 89,400 |
| 2025/12/30 | 2,447 | 2,458 | 2,407 | 2,407 | -28 | -1.1% | 85,500 |
| 2025/12/29 | 2,421 | 2,450 | 2,410 | 2,435 | +4 | +0.2% | 294,700 |
| 2025/12/26 | 2,423 | 2,436 | 2,405 | 2,431 | +8 | +0.3% | 49,600 |
| 2025/12/25 | 2,424 | 2,432 | 2,397 | 2,423 | +2 | +0.1% | 69,200 |
| 2025/12/24 | 2,429 | 2,434 | 2,398 | 2,421 | +18 | +0.7% | 63,500 |
| 2025/12/23 | 2,415 | 2,424 | 2,383 | 2,403 | -12 | -0.5% | 63,900 |
| 2025/12/22 | 2,464 | 2,464 | 2,366 | 2,415 | -22 | -0.9% | 107,200 |
| 2025/12/19 | 2,460 | 2,461 | 2,424 | 2,437 | -22 | -0.9% | 110,900 |
| 2025/12/18 | 2,413 | 2,470 | 2,413 | 2,459 | +53 | +2.2% | 67,900 |
| 2025/12/17 | 2,482 | 2,482 | 2,405 | 2,406 | -81 | -3.3% | 78,900 |
| 2025/12/16 | 2,528 | 2,530 | 2,487 | 2,487 | -13 | -0.5% | 79,300 |
| 2025/12/15 | 2,463 | 2,509 | 2,457 | 2,500 | +45 | +1.8% | 79,800 |
| 2025/12/12 | 2,454 | 2,475 | 2,412 | 2,455 | +30 | +1.2% | 83,700 |
| 2025/12/11 | 2,450 | 2,469 | 2,409 | 2,425 | -25 | -1% | 78,000 |
| 2025/12/10 | 2,449 | 2,472 | 2,430 | 2,450 | +26 | +1.1% | 92,200 |
| 2025/12/09 | 2,448 | 2,489 | 2,418 | 2,424 | -15 | -0.6% | 61,100 |
| 2025/12/08 | 2,435 | 2,467 | 2,432 | 2,439 | +14 | +0.6% | 69,600 |
| 2025/12/05 | 2,435 | 2,460 | 2,413 | 2,425 | -10 | -0.4% | 98,600 |
101~
150
件表示中 / 7241件
類似銘柄と比較する
現在ご覧いただいている「栄研化」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 栄研化 | 254,500円 | +0.2% | +2.0% | 2.28% | 40.53倍 | 1.91倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
| 持田薬 | 311,500円 | +7.7% | +11.7% | 2.73% | 11.01倍 | 0.78倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| ゼリア新薬 | 205,400円 | +6.6% | +17.7% | 2.43% | 9.05倍 | 0.84倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 90,900円 | +39.5% | - | 0.00% | 15.31倍 | 1.38倍 |
|
創薬ベンチャー老舗。買収で成長。低分子で定評の英国創薬事業、日本の製造販売が事業2本柱 |
| サンバイオ | 103,500円 | - | - | 0.00% | - | 6.06倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム